Table 2.
Calculated values of the eight indices for all lesions at baseline and on day 14 of treatment presented as means ± SD (min; max). The median percent changes after 2 weeks of treatment for responding and nonresponding tumours are also shown
| Index | Baseline | Day 14 | Change (%) | |
|---|---|---|---|---|
| Responding tumours | Nonresponding tumours | |||
| SUVmean (g/mL) | 6.1 ± 2.2 (1.7; 12.4) | 5.1 ± 1.9 (1.2; 10.4)* | −30.5 ± 15.2 (−72.4; −8.4) | −6.7 ± 29.9* (−56.5; 171.1) |
| SUVpeak (g/mL) | 7.4 ± 3.4 (1.4; 21.3) | 6.0 ± 2.9 (1.1; 18.0)* | −33.5 ± 17.0 (−74.0; −3.4) | −8.8 ± 37.1* (−8.8; 250.4) |
| SUV70 (g/mL) | 8.3 ± 3.4 (2.1; 18.5) | 6.9 ± 3.1 (1.3; 17.1)* | −31.0 ± 18.3 (−79.4; −1.5) | −7.3 ± 41.4* (−66.7; 276.3) |
| SUVmax (g/mL) | 10.5 ± 4.3 (2.5; 22.3) | 8.7 ± 3.9 (1.5; 21.1)* | −32.3 ± 18.3 (−78.1; 3.5) | −6.9 ± 37.3* (−66.7; 226.7) |
| SUVrc (g/mL) | 7.9 ± 2.7 (2.5; 14.6) | 6.7 ± 2.5 (1.7; 12.9)* | −29.3 ± 18.2 (−76.6; −0.2) | −6.3 ± 30.0* (−56.3; 151.2) |
| TLG (g) | 252.4 ± 559.3 (3.6; 3,644.9) | 161.1 ± 293.6 (2.2; 1,574.3)* | −37.2 ± 40.7 (−81.2; 133.1) | 3.3 ± 109.9* (−76.6; 834.1) |
| SUVdecon (g/mL) | 11.7 ± 4.7 (3.1; 27.2) | 9.8 ± 4.5 (1.8; 21.9)* | −28.0 ± 22.4 (−83.8; 6.7) | −6.6 ± 45.0* (−73.6; 261.6) |
| MV (mL) | 34.4 ± 66.4 (1.0; 381.5) | 27.4 ± 45.7 (1.0; 262.4)* | −4.9 ± 61.4 (−77.1; 218.2) | 6.0 ± 59.2 (−74.9; 254.9) |
*(column 3)p < 0.05, day 14 vs. baseline; *(column 5)p < 0.05, responding vs. nonresponding tumours.